key: cord-0928488-3vv3ddnj
authors: Weinbergerová, Barbora; Demel, Ivo; Víšek, Benjamin; Válka, Jan; Čerňan, Martin; Jindra, Pavel; Novák, Jan; Stejskal, Lukáš; Kovácsová, Flóra; Kabut, Tomáš; Szotkowski, Tomáš; Hájek, Roman; Žák, Pavel; Cetkovský, Petr; Král, Zdeněk; Mayer, Jiří
title: Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience
date: 2022-02-17
journal: Hematol Oncol
DOI: 10.1002/hon.2974
sha: 56da147c14cc9043e64f8de8ddf4587e1027dd5c
doc_id: 928488
cord_uid: 3vv3ddnj

COVID‐19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti‐SARS‐CoV‐2 spike protein neutralizing monoclonal antibodies (NmAbs) – bamlanivimab (72%) and casirivimab/imdevimab (28%) – efficacy among hematological patients with early‐stage COVID‐19. Mortality rate was compared to a control cohort of 575 SARS‐CoV‐2 positive hematological patients untreated with any specific anti‐COVID‐19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow‐up after NmAb administration. One third of patients (32%) were treated with an anti‐CD20 monoclonal antibody before COVID‐19 diagnosis. Median time between first COVID‐19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID‐19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID‐19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID‐19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow‐up, nine deaths (10%) were recorded ‐ all after bamlanivimab (p = 0.056) with 8% attributed to COVID‐19. Regarding “remdesivir/convalescent plasma naïve” patients, COVID‐19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS‐CoV‐2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early‐stage COVID‐19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.

with an excellent current safety profile. 1, 2 Similar results were obtained via retrospective case-control studies regarding frequency reduction of hospitalizations. 3, 4 Immunocompromized patients are generally more susceptible to COVID-19 with higher mortality reported than the general population. 5, 6 To date, only a limited number of retrospective case studies chronicling SARS-CoV-2-positive solid organ transplant patients with no worsening of symptoms and further hospitalization after NmAbs administration have been published. 7, 8 In literature, robust data on NmAbs effectivity in COVID-19 positive hematological patients are still lacking. 9 

A total of 88 hematological patients, with lymphomas, acute leukemias, and myeloma as the most frequent underlying diagnoses (72%; 64/88) were evaluated with a 97 days median follow-up (mean: 89, range: 8-138) after NmAb administration. One third of patients (32%; 28/88) were treated with an anti-CD20 monoclonal antibody (rituximab in all cases) during the 2 years prior to COVID-19 diagnosis. Around a third of patients (36%; 29/81) received at least one dose of SARS-CoV-2 vaccine before their COVID-19 diagnosis. 15% (12/82) of patients had a second COVID-19 episode when NmAb was administrated. Baseline characteristics are described in Table 1 . Among 81 evaluable cases, median time between the first COVID-19 symptom and NmAb administration was 2 days (mean: 3, range: 0-16). Median time between SARS-CoV-2 positivity and NmAb treatment was 1 day. While administering NmAb, 25 (29%), 50 (57%), 10 (11%), 2 (2%), and one (1%) of our patients had an asymptomatic, mild, moderate, severe, or critical degree of COVID-19, respectively ( Figure 1 ). Following NmAb administration, a total of 11/80 (14%) patients were treated with remdesivir, and 7 (7/80%; 9%) received (CP) together with remdesivir, respectively.

Regarding extent of infection during follow-up, 35%, 33%, 12%, 10%, and 10% of the entire group of patients had asymptomatic, mild, moderate, severe, and critical COVID-19, respectively. Among all baseline asymptomatic patients, 80% (20/25) remained asymptomatic following NmAb administration. With 78 case evaluations, median duration of COVID-19 symptoms after NmAb administration was 2.5 days (mean: 11, range: 0-101). Progression to severe/critical COVID-19 occurred among 17% (15/88) of our patients -numerically more frequently yet not significantly in the bamlanivimab versus casirivimab/imdevimab cohort (21% vs. 8%; p = 0.215). Among the entire patient group, COVID-19's course indicating baseline severity and the specific extent of infection during follow-up is detailed in Figure 1 .

Furthermore, the highest rates of COVID-19 progression to severe/critical degrees and death were observed among myelomas (29% and 12%), lymphomas (17% and 7%), acute leukemias (18% and 6%), and chronic lymphocytic leukemias (8% and 8%), respectively.

Regarding concluding oncological treatment modality, COVID-19 progression to severe or critical degree and death during follow-up were most often recorded among patients after induction/reinduction of AL (60% and 20%), autologous stem cell transplantation (SCT; 25% and 13%), and in patients treated with anti-CD20 monoclonal antibody (14% and 11%), respectively. The data are summarized in Table 2 . Table S1 . All three patients with severe or critical COVID-19 at baseline were still surviving at the time of their last follow-up.

When comparing COVID-19-related mortality in our group of NmAbs-treated "remdesivir/CP-naïve" patients (n = 69) with a control cohort of SARS-CoV-2 positive hematology patients without any COVID-19-specific treatment managed by participating centers (n = 575), significantly fewer patients died in our NmAbs treated group than in the untreated control group (16% vs. 6%, p = 0.020; 

Bamlanivimab 63 (72) Casirivimab/imdevimab 25 (28)

Abbreviations: COVID-19, coronavirus disease 2019; NmAbs, neutralizing monoclonal antibodies; SARS-CoV-2, severe acute respiratory syndromerelated coronavirus-2; SCT, stem cell transplantation.

F I G U R E 1 COVID-19 development overview from initial disease severity to the highest degree during NmAbs administration follow-up. Myeloproliferative neoplasias 0/4 (0) 0/4 (0) 6/57 (11) Chronic myeloid leukemia 0/2 (0) 0/2 (0) 1/53 (2) Myelodysplastic syndrome 0/2 (0) 0/2 (0) 9/34 (27) Other hematological diseases 1/4 (25) 1/4 (25) 4/54 (7) Last hematological therapy prior to COVID-19, n (%)

Anti-CD20 monoclonal antibody 4/28 (14) 3/28 (11) Analogous to Puing's study, all deaths in our cohort occurred after bamlanivimab infusion (p = 0.056). All seven patient fatalities attributed to COVID-19 had either concomitant advanced hematological malignancy, numerous severe comorbidities, or received treatment prior to COVID-19 with a profound and long-lasting immunosuppressive effect as indicated in Table S1 . The control cohort of SARS-CoV-2 positive hematology patients without specific COVID-19 treatment managed by participating centers exhibited a significantly higher COVID-19-related death rate than our analyzed "remdesivir/ CP-naïve" cohort of NmAbs-treated patients (16% vs. 6%, p = 0.020; Table 2 ). The highest mortality in the control cohort of patients with lymphoma, AL, high-risk myelodysplastic syndrome, multiple myeloma, and chronic lymphocytic leukemia correlated with published data. 5, 6 Significantly, among the 36% of our cohort patients becoming infected with COVID-19 following vaccination, only 5% were infec- Our study's major strength is its focus on a uniform robust multicenter cohort comprised of hematological patients compared to a control cohort without any COVID-19 specific treatment. Study constraints concern the regulatory authorization for administration of only the lowest dose of bamlanivimab with a lower efficacy.

Patients with hematological malignancies are at high risk for severe and life-threatening COVID-19 exposure. Based on our analysis results, early-administered anti-SARS-CoV-2 spike protein monoclonal neutralizing antibodies appear to be safe and effective in alleviating infection course and improving prognosis among hematological patients with early-stage COVID-19. COVID-19related mortality was substantially 3-fold lower compared to the control cohort of COVID-19 untreated hematological patients and was notably associated with advanced hematological disease and comorbidities. Our results should validate the enhanced effect of a casirivimab/imdevimab combination compared to bamlanivimab monotherapy.

anti-SARS-CoV-2 monoclonal neutralizing antibodies, bamlanivimab, casirivimab, COVID-19, hematological malignancy, imdevimab, SARS-CoV-2

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: a real-world experience

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA)

Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience

Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience

SARS-CoV-2 specific monoclonal antibody for the treatment of mild-to-moderate COVID-19 in cancer patients: a single-center experience

Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia

Mild or moderate Covid-19

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

SUPPORTING INFORMATION Additional supporting information may be found in the online version of the article at the publisher's website

Supported by Czech Republic Ministry of Health -conceptual development of research organization (FNBr, 65269705). This study was undertaken as part of our routine work.

The authors declare no competing or conflicting interests.

Barbora Weinbergerová, and Jiří Mayer -contributed to study conception and design, implemented material preparation, data collection and analysis; composed and revised manuscript.